Nanjing Well Pharmaceutical Group Co.,Ltd.

SHSE:603351 Voorraadrapport

Marktkapitalisatie: CN¥3.4b

Nanjing Well Pharmaceutical GroupLtd Beheer

Beheer criteriumcontroles 3/4

We currently do not have sufficient information about the CEO.

Belangrijke informatie

Renrong Wu

Algemeen directeur

CN¥990.7k

Totale compensatie

Percentage CEO-salarisn/a
Dienstverband CEO4.6yrs
Eigendom CEO13.7%
Management gemiddelde ambtstermijngeen gegevens
Gemiddelde ambtstermijn bestuur4.6yrs

Recente managementupdates

Recent updates

Nanjing Well Pharmaceutical GroupLtd's (SHSE:603351) Earnings Are Of Questionable Quality

Aug 26
Nanjing Well Pharmaceutical GroupLtd's (SHSE:603351) Earnings Are Of Questionable Quality

Nanjing Well Pharmaceutical GroupLtd's (SHSE:603351) Upcoming Dividend Will Be Larger Than Last Year's

Jun 07
Nanjing Well Pharmaceutical GroupLtd's (SHSE:603351) Upcoming Dividend Will Be Larger Than Last Year's

Little Excitement Around Nanjing Well Pharmaceutical Group Co.,Ltd.'s (SHSE:603351) Earnings

Jun 06
Little Excitement Around Nanjing Well Pharmaceutical Group Co.,Ltd.'s (SHSE:603351) Earnings

CEO

Renrong Wu (61 yo)

4.6yrs

Tenure

CN¥990,700

Compensatie

Mr. Renrong Wu is Chairman, Director & CEO of Nanjing Well Pharmaceutical Group Co.,Ltd. from April 08, 2020. He joined the Nanjing Well Pharmaceutical Group Co.,Ltd.in February 2000.

Bestuursleden

NaamPositieTenureCompensatieEigendom
Renrong Wu
Chairman & CEO4.6yrsCN¥990.70k13.68%
CN¥ 463.4m
Zhengsong Gao
Director4.6yrsCN¥825.60k10.42%
CN¥ 353.1m
Xinguo Chen
Director & VP4.6yrsCN¥825.60k10.42%
CN¥ 353.1m
Yamei Guan
Independent Director1.5yrsCN¥49.70kgeen gegevens
Rongwen Wu
Chairman of the Supervisory Board4.6yrsgeen gegevens2.2%
CN¥ 74.6m

4.6yrs

Gemiddelde duur

58yo

Gemiddelde leeftijd

Ervaren bestuur: 603351's board of directors are considered experienced (4.6 years average tenure).